A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Eli Lilly and Company
BeiGene
Actuate Therapeutics Inc.
Aravive, Inc.
Shanghai Henlius Biotech
OncoSec Medical Incorporated
NextCure, Inc.